AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...

Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in ...

Earnings Report 2.260 USD Q4 2021 Earnings Release 02/02/2022 Indices Commodities Currencies Stocks ...

After hours: January 24 at 7:51:49 PM EST ...

After hours: 7:51:49 pm GMT-5 ...